Osimertinib Dose Reduction Does Not Compromise OS in EGFR-Mutated Metastatic NSCLC In this retrospective study, researchers explored whether reducing osimertinib dose in EGFR-mutated metastatic NSCLC patients who experienced adverse events would worsen survival.

Reducing osimertinib dose in the first-line treatment of EGFR-mutated #mNSCLC patients due to the occurrence of adverse events has no impact on OS.

https://bit.ly/4qI4HyM

#lcsm

SFDA Granted Accelerated Approval of ANKTIVA in Combination with ICIs for Metastatic NSCLC - OncoDaily SFDA Granted Accelerated Approval of ANKTIVA in Combination with ICIs for Metastatic NSCLC / Anktiva, cancer, Headlines, Lung cancer, NSCLC, OncoDaily,

SFDA Granted Accelerated Approval of ANKTIVA in Combination with ICIs for Metastatic NSCLC

oncodaily.com/voices/sfda-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SFDA #ANKTIVA #NSCLC #mNSCLC #LungCancer

Sacituzumab Govitecan + Pembrolizumab in mNSCLC Sacituzumab govitecan combined with pembrolizumab shows promising efficacy and manageable safety in first-line metastatic NSCLC.

Sacituzumab Govitecan Plus Pembrolizumab as First-Line Therapy in mNSCLC: EVOKE-02 Study

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SacituzumabGovitecan #Pembrolizumab #mNSCLC #NSCLC #EVOKE-02

📣Updated ESMO #ClinicalPracticeGuideline recommendations in oncogene-addicted metastatic #NSCLC: more #TargetedTherapy agents now available in 1L or at resistance.
#LungCancer #mNSCLC #ESMOGuidelines

🔗 buff.ly/DSLyGib

📣Updated ESMO #ClinicalPracticeGuideline recommendations in the non-oncogene-addicted metastatic #NSCLC: new 1L Tx options approved.

🔗 buff.ly/da21Bml

#LungCancer #mNSCLC #ESMOGuidelines